Scientists from the A*STAR Infectious Diseases Labs (A*STAR IDL) have uncovered a surprising mechanism showing how mosquito saliva can alter the human body’s immune response during chikungunya virus (CHIKV) infection, contributing to Singapore’s broader efforts to strengthen infectious disease preparedness.

The research, published in Nature Communications, reveals that sialokinin, a bioactive peptide in Aedes mosquito saliva, binds to neurokinin receptors on immune cells and suppresses monocyte activation, thereby reducing inflammation and facilitating early viral dissemination. These findings offer new insight into how mosquito bites shape disease outcomes.